ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corcoran, T.E.
Right arrow Articles by Iacono, A.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corcoran, T.E.
Right arrow Articles by Iacono, A.T.
Eur Respir J 2004; 23:378-383
Copyright ©ERS Journals Ltd 2004


Preservation of post-transplant lung function with aerosol cyclosporin

T.E. Corcoran1, G.C. Smaldone2, J.H. Dauber1, D.A. Smith1, K.R. McCurry3, G.J. Burckart3, A. Zeevi4, B.P. Griffith5 and A.T. Iacono1

1 Division of Pulmonary, Allergy and Critical Care Medicine, 3 Division of Cardiothoracic Surgery, and 4 Division of Transplant Pathology, University of Pittsburgh, Pittsburgh, PA, 2 Pulmonary/Critical Care Medicine, SUNY at Stony Brook, Stony Brook, NY, and 5 Division of Cardiac Surgery and Cardiopulmonary Transplantation, University of Maryland Medical Center, Baltimore, USA

CORRESPONDENCE: T.E. Corcoran, UPMC MUH NW628, 3459 Fifth Ave., Pittsburgh, 15213, USA. Fax: 1 4126477875. E-mail: corcorante@msx.upmc.edu

Keywords: aerosol cyclosporin, aerosol deposition, lung transplantation

Received: May 28, 2003
Accepted September 24, 2003

This research was supported by grants from the National Heart, Lung and Blood Institute, and the American Lung Association. The cyclosporin powder was provided by Novartis Pharmaceuticals.

Post-lung transplant use of aerosol cyclosporin (ACsA) is considered by examining the relationship between deposited aerosol dose and effect.

In a sub-study of placebo controlled trials of ACsA as a rejection prophylaxis, 15 drug subjects received aerosol dose quantification tests to gage their ability to effectively deposit the nebulised drug in their transplanted lung(s). A total of seven placebo subjects received mock deposition tests. The deposited doses and mock doses were compared to changes in the forced expiratory volume in one second, at six time points during the 2-yr trial period (ACsA was started within 6 weeks post-transplant).

Linear relationships were demonstrated between deposited dose and improvement in lung function in the drug subjects at all intervals. Mock dose data from placebo subjects did not demonstrate similar correlation. Based on these results, subjects were grouped by dose and compared. Subjects depositing ≥5 mg of the drug in the periphery of their transplant(s) had improving pulmonary function on average. Low-dose and placebo subjects demonstrated declines, more A2–A4 rejection events in the latter portion of the trial, and more chronic rejection beyond the end of the trial.

A dose-to-effect relationship is demonstrated for aerosol cyclosporin in terms of pulmonary function and biopsy proven rejection.




This article has been cited by other articles:


Home page
NEJMHome page
A. T. Iacono, B. A. Johnson, W. F. Grgurich, J. G. Youssef, T. E. Corcoran, D. A. Seiler, J. H. Dauber, G. C. Smaldone, A. Zeevi, S. A. Yousem, et al.
A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients
N. Engl. J. Med., January 12, 2006; 354(2): 141 - 150.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.